CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

被引：66

作者：

Gillison, Maura L. ^{[1
]}

Blumenschein, George ^{[1
]}

Fayette, Jerome ^{[2
]}

Guigay, Joel ^{[3
]}

Colevas, A. Dimitrios ^{[4
]}

Licitra, Lisa ^{[5
,6
]}

Harrington, Kevin J. ^{[7
]}

Kasper, Stefan ^{[8
]}

Vokes, Everett E. ^{[9
]}

Even, Caroline ^{[10
]}

Worden, Francis ^{[11
]}

Saba, Nabil F. ^{[12
]}

Docampo, Lara Carmen Iglesias ^{[13
]}

Haddad, Robert ^{[14
]}

Rordorf, Tamara ^{[15
]}

Kiyota, Naomi ^{[16
]}

Tahara, Makoto ^{[17
]}

Monga, Manish ^{[18
]}

Lynch, Mark ^{[18
]}

Li, Li ^{[18
]}

Ferris, Robert L. ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA

[2] Ctr Leon Berard, Lyon, France

[3] Univ Cote Azur, FHU OncoAge, Ctr Antoine Lacassagne, Nice, France

[4] Stanford Univ, Stanford, CA 94305 USA

[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[6] Univ Milan, Milan, Italy

[7] Royal Marsden NHS Fdn Trust, Inst Canc Res, Natl Inst Hlth Res Biomed Res Ctr, London, England

[8] Univ Hosp, West German Canc Ctr, Essen, Germany

[9] Univ Chicago Med & Biol Sci, Chicago, IL USA

[10] Gustave Roussy, Villejuif, France

[11] Univ Michigan, Ann Arbor, MI 48109 USA

[12] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[13] Hosp Univ 12 Octubre, Madrid, Spain

[14] Dana Farber Harvard Canc Ctr, Boston, MA USA

[15] Univ Spital Zurich, Zurich, Switzerland

[16] Kobe Univ Hosp, Canc Ctr, Kobe, Hyogo, Japan

[17] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

来源：

ONCOLOGIST | 2018年 / 23卷 / 09期

关键词：

SQUAMOUS-CELL CARCINOMA; RECURRENT; STANDARD; TRIAL;

D O I：

10.1634/theoncologist.2017-0674

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

引用

页码：1079 / 1082

页数：4

共 10 条

[1] Argiris A, 2016, ANN ONCOL S, V27
[2] Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy
de Andrade, Diocesio A. P.
Machiels, Jean-Pascal
[J]. CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 211 - 217
[3] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L.
Blumenschein, G., Jr.
Fayette, J.
Guigay, J.
Colevas, A. D.
Licitra, L.
Harrington, K.
Kasper, S.
Vokes, E. E.
Even, C.
Worden, F.
Saba, N. F.
Iglesias Docampo, L. C.
Haddad, R.
Rordorf, T.
Kiyota, N.
Tahara, M.
Monga, M.
Lynch, M.
Geese, W. J.
Kopit, J.
Shaw, J. W.
Gillison, M. L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
[4] Haddad R, 2016, ANN ONCOL, V27
[5] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Harrington, Kevin J.
Ferris, Robert L.
Blumenschein, George, Jr.
Colevas, A. Dimitrios
Fayette, Jerome
Licitra, Lisa
Kasper, Stefan
Even, Caroline
Vokes, Everett E.
Worden, Francis
Saba, Nabil F.
Kiyota, Naomi
Haddad, Robert
Tahara, Makoto
Gruenwald, Viktor
Shaw, James W.
Monga, Manish
Lynch, Mark
Taylor, Fiona
DeRosa, Michael
Morrissey, Laura
Cocks, Kim
Gillison, Maura L.
Guigay, Joel
[J]. LANCET ONCOLOGY, 2017, 18 (08) : 1104 - 1115
[6] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Machiels, Jean-Pascal
Subramanian, Somasundaram
Ruzsa, Agnes
Repassy, Gabor
Lifirenko, Igor
Flygare, Annika
Sorensen, Per
Nielsen, Tina
Lisby, Steen
Clement, Paul M. J.
[J]. LANCET ONCOLOGY, 2011, 12 (04) : 333 - 343
[7] National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: breast cancer
[8] Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
Nguyen-Tan, Phuc Felix
Zhang, Qiang
Ang, K. Kian
Weber, Randal S.
Rosenthal, David I.
Soulieres, Denis
Kim, Harold
Silverman, Craig
Raben, Adam
Galloway, Thomas J.
Fortin, Andre
Gore, Elizabeth
Westra, William H.
Chung, Christine H.
Jordan, Richard C.
Gillison, Maura L.
List, Marcie
Quynh-Thu Le
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3858 - U311
[9] Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, Jan B.
Mesia, Ricard
Rivera, Fernando
Remenar, Eva
Kawecki, Andrzej
Rottey, Sylvie
Erfan, Jozsef
Zabolotnyy, Dmytro
Kienzer, Heinz-Roland
Cupissol, Didier
Peyrade, Frederic
Benasso, Marco
Vynnychenko, Ihor
De Raucourt, Dominique
Bokemeyer, Carsten
Schueler, Armin
Amellal, Nadia
Hitt, Ricardo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (11) : 1116 - 1127
[10] Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
Zenda, Sadamoto
Onozawa, Yusuke
Boku, Narikazu
Fida, Yoshiyuki
Ebihara, Mitsuru
Onitsuka, Tetsuro
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 477 - 481

← 1 →